CDT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Conduit Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.05. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.04.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Conduit Pharmaceuticals's EPS without NRI or its related term are showing as below:
Conduit Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.04.
Conduit Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.01.
The historical data trend for Conduit Pharmaceuticals's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conduit Pharmaceuticals Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
EPS without NRI | -0.05 | -0.05 | -0.17 |
Conduit Pharmaceuticals Quarterly Data | ||||||||
Dec21 | Mar22 | Sep22 | Dec22 | Mar23 | Sep23 | Dec23 | Mar24 | |
EPS without NRI | Get a 7-Day Free Trial | -0.04 | -0.02 | 0.03 | -0.02 | -0.05 |
For the Biotechnology subindustry, Conduit Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Conduit Pharmaceuticals's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conduit Pharmaceuticals (NAS:CDT) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Conduit Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Intelmed Llc | other: See Responses | 11421 GOLDEN EAGLE COURT, NAPLES FL 34120 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
David Tapolczay | director, officer: Chief Executive Officer | 32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU |
Andrew Regan | director, 10 percent owner | LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133 |
Faith L. Charles | director | ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019 |
Algo Holdings, Inc. | 10 percent owner, other: See Responses | 100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309 |
Corvus Capital Ltd. | 10 percent owner, other: See Responses | WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107 |
Freda C Lewis-hall | director | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
James Bligh | director | 38 OXBERRY AVENUE, LONDON X0 SW6 5SS |
Shaolin Capital Management Llc | 10 percent owner | 230 NW 24TH STREET, SUITE 603, MIAMI FL 33127 |
Richard Edward Feinberg | director | 2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103 |
Murphy Canyon Acquisition Sponsor, Llc | 10 percent owner | 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123 |
Chele Chiavacci Farley | director | 4 RIDGE ROAD, TUXEDO PARK NY 10987 |
Bentzen Edwin H Iv | officer: Chief Accounting Officer | 2513 BIRCH HOLLOW ST, HENDERSON NV 89044 |
Jack Kendrick Heilbron | director, officer: CEO, President, and Chairman | 16433 BRONCO LANE, POWAY CA 92064 |
From GuruFocus
By Marketwired • 10-11-2023
By Marketwired • 11-02-2023
By Marketwired • 09-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.